This study will evaluate the efficacy and safety of gantenerumab compared with placebo in patients with early Alzheimer's Disease.
Study duration for each subject will include a 12 week screening period (including the optional prescreening period), followed by a double-blind treatment period of 102 weeks of study drug treatment plus a visit 2 weeks after the last dose (week 104), and followed by the post-double-blind treatment period of two follow-up visits at 14 and 50 weeks after the last dose (weeks 116 and 152 respectively). Thus for a patient not entering the OLE, the maximum length of study is approximately 164 weeks.
Candidates for this study may or may not report disturbances in odor perception as their primary reason for seeking treatment at MUSC. This study is designed to collect long term, observational data from patients who are being treated with routine clinical care in health clinics at MUSC. Data from clinical questionnaires will be de-identified and stored in a database.
Traumatic Brain Injury is a risk factor for Alzheimer's Disease and other dementias. This study will use neuroimaging in Veterans and civilians with a history of TBI or without TBI to understand whether some of the brain changes that occur in Alzheimer's Disease are present in people with a history of TBI. The study is recruiting male and female military Veterans or civilians with or without TBI between the ages of 30 and 65.